These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 37581388)
1. Real-World Evidence on Disparities on the Initiation of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome. Yildirim M; Mueller-Hennessen M; Milles BR; Biener M; Hund H; Frey N; Giannitsis E; Salbach C J Am Heart Assoc; 2023 Aug; 12(16):e030879. PubMed ID: 37581388 [TBL] [Abstract][Full Text] [Related]
4. Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry. D'Ascenzo F; Bertaina M; Fioravanti F; Bongiovanni F; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Omedè P; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Blanco PF; Garay A; Quadri G; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Gaita F; Rinaldi M; Lüscher TF Eur J Prev Cardiol; 2020 May; 27(7):696-705. PubMed ID: 30862233 [TBL] [Abstract][Full Text] [Related]
5. Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials. Galli M; Benenati S; Franchi F; Rollini F; Capodanno D; Biondi-Zoccai G; Vescovo GM; Cavallari LH; Bikdeli B; Ten Berg J; Mehran R; Gibson CM; Crea F; Pereira NL; Sibbing D; Angiolillo DJ Eur Heart J; 2022 Mar; 43(10):959-967. PubMed ID: 34918066 [TBL] [Abstract][Full Text] [Related]
6. Comparison of Ticagrelor Versus Prasugrel for Inflammation, Vascular Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Requiring Coronary Stenting: A Prospective, Randomized, Crossover Trial. Jeong HS; Hong SJ; Cho SA; Kim JH; Cho JY; Lee SH; Joo HJ; Park JH; Yu CW; Lim DS JACC Cardiovasc Interv; 2017 Aug; 10(16):1646-1658. PubMed ID: 28838475 [TBL] [Abstract][Full Text] [Related]
7. Impact of Society Guidelines on Trends in Use of Newer P2Y Mohamed MO; Kontopantelis E; Alasnag M; Abid L; Banerjee A; Sharp ASP; Bourantas C; Sirker A; Curzen N; Mamas MA J Am Heart Assoc; 2024 May; 13(9):e034414. PubMed ID: 38700032 [TBL] [Abstract][Full Text] [Related]
8. Fewer gastrointestinal bleeds with ticagrelor and prasugrel compared with clopidogrel in patients with acute coronary syndrome following percutaneous coronary intervention. Abraham NS; Yang EH; Noseworthy PA; Inselman J; Yao X; Herrin J; Sangaralingham LR; Ngufor C; Shah ND Aliment Pharmacol Ther; 2020 Aug; 52(4):646-654. PubMed ID: 32657466 [TBL] [Abstract][Full Text] [Related]
9. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. Gimbel M; Qaderdan K; Willemsen L; Hermanides R; Bergmeijer T; de Vrey E; Heestermans T; Tjon Joe Gin M; Waalewijn R; Hofma S; den Hartog F; Jukema W; von Birgelen C; Voskuil M; Kelder J; Deneer V; Ten Berg J Lancet; 2020 Apr; 395(10233):1374-1381. PubMed ID: 32334703 [TBL] [Abstract][Full Text] [Related]
11. Features of antiplatelet therapy with P2Y12 receptor inhibitors in patients with myocardial infarction according to the Russian Register of Acute Myocardial Infarction REGION-MI. Boytsov SA; Shakhnovich RM; Tereschenko SN; Erlikh AD; Kukava NG; Pevsner DV; Rytova YK Kardiologiia; 2022 Sep; 62(9):44-53. PubMed ID: 36206137 [TBL] [Abstract][Full Text] [Related]
12. Real-world bleeding in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and prescribed different combinations of dual antiplatelet therapy (DAPT) in England: a population-based cohort study emulating a 'target trial'. Pufulete M; Harris J; Pouwels K; Reeves BC; Lasserson D; Loke YK; Mumford A; Mahadevan K; Johnson TW Open Heart; 2022 Aug; 9(2):. PubMed ID: 35961692 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of Microvascular Injury in Revascularized Patients With ST-Segment-Elevation Myocardial Infarction Treated With Ticagrelor Versus Prasugrel. van Leeuwen MAH; van der Hoeven NW; Janssens GN; Everaars H; Nap A; Lemkes JS; de Waard GA; van de Ven PM; van Rossum AC; Ten Cate TJF; Piek JJ; von Birgelen C; Escaned J; Valgimigli M; Diletti R; Riksen NP; van Mieghem NM; Nijveldt R; van Royen N Circulation; 2019 Jan; 139(5):636-646. PubMed ID: 30586720 [TBL] [Abstract][Full Text] [Related]
14. Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Analysis from the Acute Coronary Syndrome Israeli Survey. Eliaz R; Mengesha B; Ovdat T; Iakobishvili Z; Hasdai D; Kheifets M; Klempfner R; Beigel R; Kalmanovich E; Alcalai R; Levi A Cardiology; 2022; 147(2):113-120. PubMed ID: 34808635 [TBL] [Abstract][Full Text] [Related]
15. Ticagrelor Utilization in Patients With Non-ST Elevation Acute Coronary Syndromes in Romania. Cotoban AG; Udroiu CA; Vinereanu D Am J Ther; 2021 Apr; 28(3):e271-e283. PubMed ID: 33852478 [TBL] [Abstract][Full Text] [Related]
16. Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70 years and older--rationale and design of the POPular AGE study. Qaderdan K; Ishak M; Heestermans AA; de Vrey E; Jukema JW; Voskuil M; de Boer MJ; van't Hof AW; Groenemeijer BE; Vos GJ; Janssen PW; Bergmeijer TO; Kelder JC; Deneer VH; ten Berg JM Am Heart J; 2015 Nov; 170(5):981-985.e1. PubMed ID: 26542508 [TBL] [Abstract][Full Text] [Related]
17. Real-World Data of Prasugrel vs. Ticagrelor in Acute Myocardial Infarction: Results from the RENAMI Registry. De Filippo O; Cortese M; D Ascenzo F; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Montefusco A; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Blanco PF; Garay A; Quadri G; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Rinaldi M Am J Cardiovasc Drugs; 2019 Aug; 19(4):381-391. PubMed ID: 31030413 [TBL] [Abstract][Full Text] [Related]
18. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985 [TBL] [Abstract][Full Text] [Related]
19. Comparison of P2Y12 receptor inhibitors in patients with ST-elevation myocardial infarction in clinical practice: a propensity score analysis of five contemporary European registries. De Luca L; Zeymer U; Claeys MJ; Dörler J; Erne P; Matter CM; Radovanovic D; Weidinger F; Lüscher TF; Jukema JW; Eur Heart J Cardiovasc Pharmacother; 2021 Mar; 7(2):94-103. PubMed ID: 31965164 [TBL] [Abstract][Full Text] [Related]
20. Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis. Wang Z; Zhou DY; Su Y; Si LY; Xu Q BMC Cardiovasc Disord; 2020 Mar; 20(1):130. PubMed ID: 32164560 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]